tbuckley/cabot-search huggingface dataset:
Phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel in patients with completely resected non-small cell lung cancer
Authors: M. Sugaya, K. Sugio, A. Nagashima, R. Nakanishi, H. Sakata, K. Nakanishi, K. Ono, H. Uramoto, T. Hanagiri, K. Yasumoto
Journal: Journal of Clinical Oncology (2005)

7258 Background: Cisplatin-based adjuvant chemotherapy improves survival among patients with NSCLC. This phase II trial assessed the efficacy and safety profiles of bi-weekly schedule of carboplatin and paclitaxel as adjuvant chemotherapy. Methods: Eligibility criteria included: completely resected NSCLC (Stage IB, IIA/B, IIIA/B), PS 0–1, age less than 80, no prior chemotherapy/radiotherapy, adequate hematological, liver, renal functions. The patients received chemotherapy with paclitaxel 90mg/m2 and carboplatin AUC3 every 2 weeks x6, after surgery. Primary endpoints were adverse events and disease-free survival. Secondary endpoint were compliance. Results: Seventy two patients were enrolled in this study and 67 patients were evaluable for disease-free survival and adverse events. Fifty patients (74.6%) completed all cycles of therapy, and the average number of cycles administered was 5.1. Patient characteristics were median age 64 (range; 33–79); 50 males and 17 females. They included 41 adenocarcinomas, 21 squamous cell carcinomas and 4 others. Twenty four patients were in Stage IB, 16 in II, 21 in IIIA, 6 in IIIB. The hematologic and the non-hematologic adverse events (grade 3/4) occurred 9 and 6 patients, respectively. The median follow-up period was 735 days (141–1191 days). The 2-year survival rates and disease-free survival of 67 patients were 91.9% and 79.7%, respectively. The 2-year survival rate n stage IB-II and III-IV were 97.5% and 84.2%, respectively. The 2-year disease-free survival of patients with IB-II were 86.8% and that of patients with III-IV were 70.7%. Conclusions: Bi-weekly schedule of carboplatin and paclitaxel as adjuvant chemotherapy was well tolerated in elderly NSCLC patients, and seem to be a candidate arm of further trial. No significant financial relationships to disclose.
Csk overexpression makes T cell dummy
Authors: S. Wälchli, E.M. Inderberg, N. Mensali, B. Stenvik, M. Oksvold, C.A.M. Progida, O. Bakke, L.-E. Fallang, G. Kvalheim, J.H. Myklebust
Journal: Annals of Oncology (2016)
Infectious Complications In a Prospective Cohort of Community Based Newly Diagnosed Patients with Chronic Lymphocytic Leukemia (CLL).
Authors: Jonathan Moreira, Timothy Call, Kari Rabe, Randy Wendt, Clive S. Zent, Neil E. Kay, Deborah Bowen, Jose Leis, Susan Slager, Jon Wilson, Tait Shanafelt
Journal: Blood (2010)
Neglect or good practice? Authors’ reply to letters by Rhein and Degner
Authors: Mark J Bolland, Alison Avenell, Andrew Grey
Journal: BMJ (2017)

We wonder what compelled Rhein to accuse us of “condescending neglect” of northern Britain, especially given that one of us lives in northeast Scotland.12 She says that the evidence for vitamin D supplements is good enough for her, citing meta-analyses of randomised trials for patients in critical care, cancer mortality, and asthma.1 But these meta-analyses have substantial limitations that led their authors34 …
Ocular Adnexal Marginal Zone Lymphomas (OAMZL): Lack of Evidence for Chlamydia Psittaci (C. Psittaci) Infection in a Clinicopathologic Study from a Single Institution
Authors: Brayan Marcel Merchán, Anny Jaramillo, Teresa Tortola, Pau Abrisqueta, Josep Castellvi, Ramón Medel, Katia Flores, Javier Hernandez, Mercedes Gironella, Andres Lopez-Hernandez, Francesc Bosch
Journal: Blood (2014)
Merkel Cell Carcinomas Arising in Autoimmune Disease Affected Patients Treated with Biologic Drugs, Including Anti-TNF
Authors: John Charles Rotondo, Ilaria Bononi, Andrea Puozzo, Marcello Govoni, Valentina Foschi, Giovanni Lanza, Roberta Gafà, Pauline Gaboriaud, Françoise Antoine Touzé, Rita Selvatici, Fernanda Martini, Mauro Tognon
Journal: Clinical Cancer Research (2017)

Abstract Purpose: The purpose of this investigation was to characterize Merkel cell carcinomas (MCC) arisen in patients affected by autoimmune diseases and treated with biologic drugs. Experimental Design: Serum samples from patients with MCC were analyzed for the presence and titer of antibodies against antigens of the oncogenic Merkel cell polyomavirus (MCPyV). IgG antibodies against the viral oncoproteins large T (LT) and small T (ST) antigens and the viral capsid protein-1 were analyzed by indirect ELISA. Viral antigens were recombinant LT/ST and virus-like particles (VLP), respectively. MCPyV DNA sequences were studied using PCR methods in MCC tissues and in peripheral blood mononuclear cells (PBMC). Immunohistochemical (IHC) analyses were carried out in MCC tissues to reveal MCPyV LT oncoprotein. Results: MCPyV DNA sequences identified in MCC tissues showed 100% homology with the European MKL-1 strain. PBMCs from patients tested MCPyV-negative. Viral DNA loads in the three MCC tissues were in the 0.1 to 30 copy/cell range. IgG antibodies against LT/ST were detected in patients 1 and 3, whereas patient 2 did not react to the MCPyV LT/ST antigen. Sera from the three patients with MCC contained IgG antibodies against MCPyV VP1. MCC tissues tested MCPyV LT-antigen–positive in IHC assays, with strong LT expression with diffuse nuclear localization. Normal tissues tested MCPyV LT–negative when employed as control. Conclusions: We investigated three new MCCs in patients affected by rheumatologic diseases treated with biologic drugs, including TNF. A possible cause–effect relationship between pharmacologic immunosuppressive treatment and MCC onset is suggested. Indeed, MCC is associated with MCPyV LT oncoprotein activity. Clin Cancer Res; 23(14); 3929–34. ©2017 AACR.
Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial
Authors: Robert Glynne-Jones, David Sebag-Montefiore, Helen M Meadows, David Cunningham, Rubina Begum, Fawzi Adab, Kim Benstead, Robert J Harte, Jill Stewart, Sandy Beare, Allan Hackshaw, Latha Kadalayil
Journal: The Lancet Oncology (2017)

Guidelines for anal cancer recommend assessment of response at 6-12 weeks after starting treatment. Using data from the ACT II trial, we determined the optimum timepoint to assess clinical tumour response after chemoradiotherapy.
255P Predictive value of ERCC1, ERCC2, ERCC4, and glutathione S-transferase P1 for FOLFIRINOX in unresectable pancreatic cancer
Authors: S. Tezuka, M. Ueno, S. Ohkawa, A. Hirotani, Y. Totsuka, S. Moriya, S. Kobayashi, M. Morimoto, Y. Nakamura, Y. Miyagi, S. Maeda
Journal: Annals of Oncology (2016)
Simultaneous Assessment of Eosinophil Biomarkers in Eosinophilic Esophagitis Patients
Authors: Evelyn L. Angulo, Mats W. Johansson, Elizabeth A. Schwantes, Paul S. Fichtinger, Shelly M. Cook, Eric A. Gaumnitz, Sameer K. Mathur
Journal: Journal of Allergy and Clinical Immunology (2017)
PRT060318, a Novel Syk Inhibitor, Prevents Heparin-Induced Thrombocytopenia in a Transgenic Mouse Model
Authors: Michael P. Reilly, Uma Sinha, Pierrette Andre, Scott M. Taylor, Yvonne Pak, Francis R. DeGuzman, Nisha Nanda, Anjali Pandey, Steven E. McKenzie
Journal: Blood (2008)
Identifying lifestyle and genetic factors to prevent recurrence of non-muscle invasive bladder cancer in a prospective cohort study at Kaiser Permanente (the Be-Well study).
Authors: Marilyn L. Kwan, Lawrence H. Kushi, Virginia P. Quinn, Nirupa R. Ghai, Janise M. Roh, Tracy A. Becerra, Adriana A. Martinez, Kimberly L. Cannavale, Alexander S. Carruth, Valerie S. Lee, Isaac J. Ergas, Ronald K. Loo, David S. Aaronson, Yuesheng Zhang, Christine B. Ambrosone, Li Tang
Journal: Journal of Clinical Oncology (2016)

e296 Background: Bladder cancer is one of the top 10 incident cancers. Most cases (75%) are diagnosed as non-muscle invasive disease (NMID), yet NMID typically recurs (70%) and a subset (25%) progresses to muscle-invasive disease. Be-Well is a 5-year, NCI-funded prospective cohort study of NMID bladder cancer patients at Kaiser Permanente Northern (KPNC) and Southern California (KPSC). The goal is to examine diet and lifestyle factors and prognosis, with an emphasis on cruciferous vegetable (CV) intake and their unique isothiocyanate (ITC) content, the modifying effect of polymorphisms of ITC-metabolizing genes, and interactions with treatment. Our prior work suggests that dietary ITCs may prevent disease recurrence and progression in NMID patients. Methods: Newly-diagnosed patients with NMID (Ta, Tis, T1), who are English-speaking, KP members, and ≥ 21 years of age, are rapidly ascertained from electronic pathology reports and enrolled on average 2.6 months post-diagnosis. Baseline participation consists of a telephone interview including a food frequency questionnaire focused on CV intake, and providing blood and urine samples. Patients will be contacted for follow-up interviews and urine samples at 12 and 24 months. Smoking, medication use, occupational exposures, physical activity, quality of life, and urinary function are also queried. Biospecimens are processed and assayed at Roswell Park Cancer Institute. Strong support for Be-Well by KP urologists will promote dissemination of study results in patient care and recommendations. Results: Recruitment began in February 2015. To date, 159 patients have completed the baseline interview, representing 76% male and 24% female, and 80% White, 8% Black, 6% Hispanic, 3% Asian, and 3% Other. Urine specimens have been collected from 87% of consented patients. Blood specimens have been collected from 87% of KPNC patients, with collection at KPSC to begin in Fall 2015. Conclusions: The Be-Well Study is poised to be the largest and most comprehensive study to answer critical questions related to prognosis, quality of life, and care in patients diagnosed with early-stage bladder cancer.
Comprehensive profiling of thyroid and lung cancers by anchored multiplex PCR and next-generation sequencing
Authors: J. Stahl, J.D. Haimes, L. Johnson, J. Covino, N. Manoj, M. Bessette, E. Baravik, A. Licon, R.D. Walters, L. Griffin, J.W. Myers, B. Culver, B. Kudlow
Journal: Annals of Oncology (2016)
Six Month Freedom From Steroid Failure Complements Day 28 Response to Steroids As a Predictor of Survival After Acute Graft-Versus-Host Disease Treatment
Authors: Salyka M. Sengsayadeth, Madan Jagasia, John P. Greer, Heidi Chen, Stacey Goodman, Wichai Chinratanalab, Adetola A Kassim, Bipin N. Savani, Brian G Engelhardt
Journal: Blood (2012)
PDTB-17. PRE-CLINICAL EVALUATION OF TRAMETINIB IN A GENETICALLY ENGINEERED MOUSE MODEL OF DIPG
Authors: Tammy Hennika, Guo Hu, Oren Becher
Journal: Neuro-Oncology (2016)

Diffuse intrinsic pontine glioma (DIPG) is a fatal brain cancer of childhood with a median survival of less than 1 year from diagnosis. The mitogen-activated protein kinase (MAPK) pathway (RAS-RAF-MEK1/2-ERK1/2) is a known signaling cascade in glioma tumorigenesis. Trametinib is an allosteric inhibitor of MEK1/2. We performed a pre-clinical study using a genetically engineered mouse model of DIPG driven by PDGF-B signaling, p53 loss, and ectopic H3.3-K27M expression to investigate the efficacy of trametinib both in vitro and in vivo. In vitro, trametinib significantly reduced cell proliferation in 3 separate H3.3-K27M tumor cell lines at very low concentrations (IC50s: 0.01µM, 0.06µM, 0.11µM). Western blot analysis showed complete inhibition of ERK phosphorylation (p-ERK 1/2), a MEK downstream target, after treating tumor cells with 10µM of trametinib for 30 minutes. In vivo, symptomatic tumor mice treated with trametinib at 3mg/kg or vehicle once daily for 3 days (n = 6 in each group) or 5 days (n = 3 in each group) via intraperitoneal injections did not show a significant decrease in tumor cell proliferation or a significant increase in apoptosis. Pharmacokinetic analysis after trametinib administration for 3 days demonstrated an average drug concentration of 0.383µM in normal cortex and 0.699µM in tumor tissue, and after 5 days 0.248µM in normal cortex and 0.501µM in tumor tissue. Our pre-clinical study demonstrates that trametinib significantly inhibits the proliferation of DIPG tumor cells as well as the MAPK pathway in vitro. Pharmacokinetic analysis shows that trametinib total concentrations in the tumor are greater than its in vitro IC50 (BrdU assay). As short-term in vivo studies did not show a significant decrease in cell proliferation, or a significant increase in apoptosis, trametinib has limited in vivo efficacy as a single agent in a genetic mouse model of DIPG.
Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-Fluorouracil with or without docetaxel: retrospective analysis of EORTC24971 study.
Authors: Amanda Psyrri, Catherine Fortpied, George Koutsodontis, Margaritis Avgeris, Jessica Menis, Leslie Herman, Livia Giurgea, Eva Remenar, Johannes Albertus Langendijk, Ahmad Awada, Pieter H. M. De Mulder, Heinz Roland Kienzer, Marian Degardin, Athanassios Kotsinas, Sjoukje Oosting, Vincent Gregoire, Lisa F. Licitra, Jan B. Vermorken
Journal: Journal of Clinical Oncology (2015)

6061 Background: EORTC 24971 was phase III trial demonstrating superiority of induction regimen TPF over PF, in terms of progression-free (PFS) and overall survival (OS) in locally advanced unresectable HNSCC. We conducted prospective-retrospective analysis with the aim to evaluate whether only HPV negative patients(pts) derive benefit from adding docetaxel to PF, in which case de-intensifying induction treatment in HPV+ patients could be considered. Methods: HNSCC specimens were collected from 1999 until 2002. Pre-therapy tumor biopsies (blocks or slides) were assessed for high risk (HR) HPV by p16 immunohistochemistry, PCR and quantitative PCR (qPCR). HPV DNA+ and/or p16+ tumors were subjected to in situ hybridization (ISH) and HPV E6/7 oncogene expression analysis by quantitative reverse transcriptase. The primary and secondary objectives were to evaluate the value of HPV/p16 status as predictive factor of treatment benefit in terms of PFS and OS, respectively. The predictive effect was analyzed based on the model used in the primary analysis of the study with the addition of a treatment by marker interaction term and tested at two-sided 5% significance level. Results: A total 120 of 358 patients had available tumor samples and 59 of them had oropharyngeal cancer. Median follow-up was 8.7 years and data updated through 2011. Sixteen of 119 (13%) evaluable samples were p16 positive and 20 of 79 (25%) evaluable tumors were HPV+ by PCR or qPCR. 12/31 pts assessed with HPV DNA ISH were positive and 12 of 28 pts assessed for HPV16mRNA were positive. The pre-planned analysis showed no statistical evidence of predictive value of p16/HPV status for PFS (p = 0.287) or OS (p = 0.118). Conclusions: The incidence of HPV positivity was low in EORTC 24971 cohort. In this prospective- retrospective analysis only powered to detect a large treatment by marker interaction there was no statistical evidence that treatment effect found overall was different in magnitude in HPV positive or HPV negative patients. These results do not justify selection of TPF versus PF according to HPV status.
Widespread and Opponent fMRI Signals Represent Sound Location in Macaque Auditory Cortex
Authors: Michael Ortiz-Rios, Frederico A.C. Azevedo, Paweł Kuśmierek, Dávid Z. Balla, Matthias H. Munk, Georgios A. Keliris, Nikos K. Logothetis, Josef P. Rauschecker
Journal: Neuron (2017)
Clonotypic IgG B Cells in Waldenstrom Macroglobulinemia Cells Are Derived from Multiple Post-Transformed B Cells That Have Undergone Isotype Switch Recombination.
Authors: Jitra Kriangkum, Brian J. Taylor, Erin Strachan, Tony Reiman, Andrew R. Belch, Michael J. Mant, Linda M. Pilarski
Journal: Blood (2005)
Co-Transplantation of MSC Improves the Engraftment of HSC after Auto-iBMT in Non-Human Primates.
Authors: Shigeo Masuda, Yoko Obara, Naohide Ageyama, Hiroaki Shibata, Tamako Ikeda, Yasuji Ueda, Keiya Ozawa, Yutaka Hanazono
Journal: Blood (2008)
Oncologic outcomes of partial versus radical nephrectomy for unilateral Wilms tumor.
Authors: N. G. Cost, J. D. Lubahn, H. A. Penn, C. F. Granberg, B. J. Schlomer, J. E. Wickiser, D. Rakheja, P. C. Gargollo, D. Leonard, L. A. Baker, G. Raj, V. Margulis
Journal: Journal of Clinical Oncology (2011)

9561 Background: According to the Children's Oncology Group (COG) and International Society of Pediatric Oncology (SIOP), the recommended surgical management for unilateral Wilms tumor (UWT) is radical nephrectomy (RN). However, recent data demonstrate that when oncologically feasible, renal preserving surgery decreases the likelihood of chronic renal disease and associated comorbidities. Thus, we analyzed outcomes of those undergoing partial nephrectomy (PN) compared to RN for UWT. Methods: We searched PubMed using: “Wilms tumor,” “Nephroblastoma,” “PN” and “Nephron Sparing Surgery.” Reviewing citations to eliminate repeat reports we found 115 patients who had PN for UWT. These reports were analyzed for: stage, recurrence, recurrence location, overall survival (OS) and time to event. 82 cases had adequate data to analyze. In comparison, the same endpoints were collected on all children who had RN for UWT from 1985-2010 at Childrens Med Ctr Dallas. Results: Of the 82 PN patients, 64 were stage I, 10 stage II, 6 stage III and 2 stage IV; however, this was a mix of patients staged/treated by SIOP or COG protocols. Of the 121 RN patients, 24 were stage I, 45 stage II, 29 stage III and 23 stage IV. All of these were treated by COG protocols. In the PN group, there were 9 total recurrences, 6 local recurrences and 4 deaths. At a median follow-up of 48mo (3-372), the recurrence free survival (RFS), local RFS and OS were 89.1%, 92.7% and 95.1% respectively. In the RN group, there were 20 total recurrences, 6 local recurrences and 6 deaths. At a median follow up of 69.3mo (0.1-214), the RFS, local RFS and OS were of 83.1%, 95.0% and 95.0% respectively. Using a Cox Regression Analysis to control for stage, there were no statistically significant differences in the above oncologic outcomes between the groups. The Hazard Ratio (HR) for the RN vs. PN group was: RFS HR=0.95 (95% CI 0.39-2.34), local RFS HR=0.77 (0.21-2.9) and OS HR=0.45 (0.17-4.39). Conclusions: Based on reported data, the oncologic outcomes of PN for UWT in a select population do not appear to differ from those of RN. With the potential for renal preservation and its associated benefits, PN for appropriately selected patients should be studied in a prospective, cooperative trial versus RN to definitively assess its role in UWT.
Low Absolute Lymphocyte Count and Addition of Rituximab Confer High Risk for Interstitial Pneumonia In Patients with Diffuse Large B Cell Lymphoma
Authors: Yuan-Bin Yu, Yu-Chung Huang, Chia-Jen Liu, Jih-tung Pai, Hsueh-Ju Lu, Chun-Yu Liu, Ying-Chung Hong, Liang-Tsai Hsiao, Jyh-Pyng Gau, Hui-Chi Hsu, Tzeon-Jye Chiou, Jin-Hwang Liu, Cheng-Hwai Tzeng
Journal: Blood (2010)
Characterization Of The Effects Of Mutated EZH2 On Expression and Epigenome In a Mouse Lymphoma Model
Authors: Tobias Berg, Silvia Thoene, Damian Yap, Tracee Wee, Nathalie Schoeler, Patty Rosten, Emilia Lim, Misha Bilenky, Andrew J Mungall, Thomas Oellerich, Patricia Umlandt, Anisa Salmi, Harry Chang, Lisa Yue, David Lai, Grace Cheng, Hubert Serve, Ryan D Morin, Martin Hirst, Marco A. Marra, Gregg B. Morin, Randy D. Gascoyne, Samuel A. Aparicio, R. Keith Humphries
Journal: Blood (2013)
How clinicians make decisions regarding surveillance and treatment of colorectal cancer (CRC) patients.
Authors: Amanda Cuddy, Katherine Van Loon, Y. Nancy You, Chung-Yuan Hu, Amanda Beth Francescatti, Caprice Christian Greenberg, Alan P. Venook, Deborah Schrag, George J. Chang
Journal: Journal of Clinical Oncology (2016)

263 Background: The goal of post-treatment surveillance of CRC patients is to identify recurrences among patients eligible for salvage surgery or palliative chemotherapy. However, patient ineligibility for treatment of recurrence may contribute to variation in surveillance practices. The aim of this study was to evaluate patient factors that affect clinician decisions regarding surveillance and salvage treatment eligibility among CRC patients. Methods: A custom 41-item survey was developed, incorporating modified criteria for adult comorbidity evaluation. A convenience sample of physicians who treat CRC was recruited from the ALLIANCE GI Cancer Committee. All participants completed an anonymous written survey of objective and subjective information about salvage treatment eligibility and the impact on surveillance in these patients. Results: Respondents were medical oncologists (n = 16; n = 11 with &gt; 10 yrs experience) and surgical oncologists (n = 4). Patients with average comorbidity were considered ineligible for curative salvage surgery at median age 85 yrs (IQR: 80, 90), life expectancy 3 yrs (IQR: 2, 4.8) or ECOG ≥ 2 (IQR: 2,3). Patients were considered ineligible for palliative chemotherapy at median age 90 (IQR: 80, 92.5), life expectancy ≤ 2 years (IQR: 1.5, 3) or ECOG status ≤ 3 (IQR: 3, 3). Patients with above average comorbidity were considered ineligible for salvage surgery at median age 80 yrs (IQR: 75, 80) and palliative chemotherapy at median age 80 yrs (IQR: 75, 85). 8 comorbidities were identified by &gt; 75% of the respondents as determinants of treatment ineligibility. 12 respondents (60%) indicated follow-up of patients ineligible for treatment should be continued based on patient desire, ongoing management of late effects, and continuity of care. However, a majority (n = 15) responded that clinic visits only should be continued without further testing. Conclusions: Considerable agreement was observed regarding patient characteristics that lead to ineligibility for treatment of recurrent disease. This information can aid shared clinical decision-making for post-treatment surveillance strategies and may potentially reduce variation in surveillance practice.
A Novel IL-12-TIM-3 Pathway Induces T Cell Exhaustion and Predicts Reduced Survival In Patients with Follicular B-Cell Non-Hodgkin Lymphoma
Authors: Zhi-Zhang Yang, Deanna Grote, Steven Ziesmer, Toshiro Niki, Mitsuomi Hirashima, Anne J. Novak, Thomas E. Witzig, Stephen M. Ansell
Journal: Blood (2010)
Rapid Desensitization Premedication to paclitaxel: Are Esteroids and Antihistamines Useful?
Authors: Paula Lopez-Gonzalez, Laura V. Carpio-Escalona, Lorena Bernal-Rubio, Patricia Lopez-de los santos, Pilar Berges-Gimeno, Ricardo Madrigal-Burgaleta
Journal: Journal of Allergy and Clinical Immunology (2017)
Chromosomal Abnormalities in Philadelphia Chromosome (Ph)-Negative Metaphases Appearing during Novel Tyrosine Kinase Inhibitors (NTKI) Therapy in Patients (pts) with Chronic Myeloid Leukemia (CML) after Imatinib-Failure.
Authors: Elias Jabbour, Hagop Kantarjian, Lynne Abruzzo, Francis Giles, Mary Beth Rios, Jorge Cortes
Journal: Blood (2006)